GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (8)
  • 1
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 24, No. 3 ( 2015-03-01), p. 627-630
    Abstract: Background: Two recent genome-wide association studies (GWAS) identified SNPs in or near four genes related to circulating 25-hydroxyvitamin D [25(OH)D] concentration. To examine the hypothesized inverse relationship between vitamin D status and breast cancer, we studied the associations between SNPs in these genes and breast cancer risk in a large pooled study of 9,456 cases and 10,816 controls from six cohorts. Methods: SNP markers localized to each of four genes (GC, CYP24A1, CYP2R1, and DHCR7) previously associated with 25(OH)D were genotyped and examined both individually and as a 4-SNP polygenic score. Logistic regression was used to estimate the associations between the genetic variants and risk of breast cancer. Results: We found no association between any of the four SNPs or their polygenic score and breast cancer risk. Conclusions: Our findings do not support an association between vitamin D status, as reflected by 25(OH)D–related genotypes, and breast cancer risk. Impact: These findings may contribute to future meta-analyses and scientific review articles, and provide new data about the association between vitamin D–related genes and breast cancer. Cancer Epidemiol Biomarkers Prev; 24(3); 627–30. ©2014 AACR.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2006
    In:  Cancer Research Vol. 66, No. 5 ( 2006-03-01), p. 2869-2875
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 66, No. 5 ( 2006-03-01), p. 2869-2875
    Abstract: Impaired glucose metabolism and hyperinsulinemia have been hypothesized to increase breast cancer risk. However, findings from observational studies relating blood concentrations of hyperinsulinemia markers to breast cancer risk have been inconsistent. We prospectively evaluated whether hemoglobin A1c (HbA1c) concentrations predict breast cancer risk in a large female cohort. We included 27,110 female participants of the Women's Health Study who were, at baseline, free of cancer and had usable blood specimens as well as sufficient information on potential risk factors for breast cancer. Relative risks (RR) and 95% confidence intervals (95% CI) were estimated from Cox proportional hazards regression models. All Ps were two sided. During an average of 10 years of follow-up, 790 incident cases of invasive breast cancer were confirmed. Higher baseline HbA1c levels were not associated with an increased risk of breast cancer. The multivariate RR for the highest relative to the lowest quintile of HbA1c levels was 0.87 (95% CI, 0.69-1.10; Ptrend = 0.22). Higher HbA1c levels were also not associated with an increased risk of breast cancer according to alternative clinical cutoff points for HbA1c or in the analyses stratified by body mass index or according to certain tumor characteristics. However, a weakly inverse association was noted among postmenopausal women, especially among those who had never used hormone therapy. There was also a weakly inverse association between HbA1c levels and estrogen receptor–negative breast tumors. These data suggest that higher HbA1c concentrations do not seem to increase risk of breast cancer among apparently healthy women. (Cancer Res 2006; 66(5): 2869-75)
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2006
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2005
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 14, No. 12 ( 2005-12-01), p. 3010-3012
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 14, No. 12 ( 2005-12-01), p. 3010-3012
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2005
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Prevention Research Vol. 4, No. 8 ( 2011-08-01), p. 1172-1180
    In: Cancer Prevention Research, American Association for Cancer Research (AACR), Vol. 4, No. 8 ( 2011-08-01), p. 1172-1180
    Abstract: Inflammation, as measured by the circulating inflammatory marker high-sensitivity C-reactive protein (hsCRP), has been associated with cardiovascular disease. However, data about CRP and risk of colorectal cancer have been conflicting. The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events. We examined whether serum hsCRP modified these results. We measured hsCRP from serum specimens provided at study entry by patients enrolled in the APC trial. Patients were stratified according to use of low-dose aspirin, randomized to receive 3 years of treatment with placebo, 200-mg-bid celecoxib, or 400-mg-bid celecoxib, and underwent follow-up colonoscopies at years 1 and 3. Among 1,680 patients, the estimated 3-year cumulative incidence of adenoma was 42% for patients with hsCRP & lt;1 mg/L, compared with 43% [relative risk (RR) = 1.02; 95% CI = 0.85–1.22] for hsCRP 1–3 mg/L, and 41% (RR = 1.10; 95% CI = 0.90–1.34) for hsCRP & gt;3 mg/L. The effect of celecoxib on adenoma recurrence did not vary among patients with high ( & gt;3 mg/L) compared with low (≤3 mg/L) hsCRP. However, among patients with high hsCRP, the RR of cardiovascular events compared with placebo was 2.27 (95% CI = 0.72–7.14) for those randomized to celecoxib 200-mg-bid and 3.28 (95% CI = 1.09–9.91) for 400-mg-bid. In contrast, among patients with low hsCRP, the corresponding RRs were 0.99 (95% CI = 0.53–1.83) and 1.11 (95% CI = 0.61–2.02). hsCRP may predict risk of celecoxib-associated cardiovascular toxicity but not adenoma recurrence or celecoxib treatment efficacy. Patients with low hsCRP may be a subgroup with a favorable risk-benefit profile for celecoxib chemoprevention. Cancer Prev Res; 4(8); 1172–80. ©2011 AACR.
    Type of Medium: Online Resource
    ISSN: 1940-6207 , 1940-6215
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2422346-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 24, No. 8 ( 2015-08-01), p. 1199-1206
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 24, No. 8 ( 2015-08-01), p. 1199-1206
    Abstract: Background: C-reactive protein (CRP) has been evaluated as a risk factor for breast cancer in epidemiologic studies. However, results from prospective studies are inconsistent. Methods: We evaluated the association using prediagnostic blood samples in a case–control study nested within the Nurses' Health Study (NHS) and the full cohort of the Women's Health Study (WHS). A total of 943 cases in the NHS and 1,919 cases in the WHS contributed to the analysis. Conditional logistic regression and Cox proportional hazards model were used in the NHS and WHS, respectively. We pooled our results with prior prospective studies using random effect meta-analysis. Results: In the NHS, higher CRP levels were associated with a suggestively increased risk of breast cancer [quintile 5 vs. 1: relative risk (RR), 1.27; 95% confidence interval (CI), 0.93–1.73; Ptrend = 0.02]; results did not vary significantly by tumor invasiveness or hormone receptor status. However, no association was observed in the WHS for overall risk (quintile 5 vs. 1: RR, 0.89; 95% CI, 0.76–1.06; Ptrend = 0.38) or by tumor invasiveness or hormone receptor status. The meta-analysis (including 5,371 cases from 11 studies) showed a modestly increased risk among women in the highest versus lowest categories of CRP (RR, 1.26; 95% CI, 1.07–1.49). Conclusions: Existing data from prospective studies suggest that CRP, a nonspecific marker of inflammation, is modestly positively associated with breast cancer risk. Impact: Our findings provide support to the concept that inflammation can influence breast cancer development. Cancer Epidemiol Biomarkers Prev; 24(8); 1199–206. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2016
    In:  Molecular Cancer Research Vol. 14, No. 1_Supplement ( 2016-01-01), p. B79-B79
    In: Molecular Cancer Research, American Association for Cancer Research (AACR), Vol. 14, No. 1_Supplement ( 2016-01-01), p. B79-B79
    Abstract: Background: Glycoproteins mediate inflammation and are essential for various biological functions including cell growth and division of normal and malignant tissues. We hypothesized that GlycA, a novel systemic inflammatory biomarker of protein glycan N-acetyl groups, is related to incident colorectal cancer and mortality. Methods: Using observational follow-up of a randomized trial, we evaluated the prospective association of baseline plasma GlycA with incident colorectal cancer (CRC) risk in 27,495 female health professionals aged 45 years or older and free of cancer and cardiovascular disease in the Women's Health Study (WHS, ClinicalTrials.gov: NCT00000479) with baseline blood samples and median follow-up of 19 years. Baseline plasma GlycA was measured by nuclear magnetic resonance spectroscopy (LipoScience, Inc, Raleigh, NC) from the N-acetyl methyl groups of N-acetylglucosamine residues located on specific glycan branches of plasma proteins (mainly from the acute phase glycoproteins 1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin and transferrin). Plasma GlycA was categorized into quartiles and per 1-standard deviation (SD) increment. All cancer and mortality endpoints were confirmed from medical records. We compared GlycA to other established biomarkers of systemic inflammation, high-sensitivity C-reactive protein (hsCRP), fibrinogen, and soluble intercellular adhesion molecule-1 (sICAM). Results: During median follow-up of 19 years, 336 incident colorectal cancer cases and 103 colorectal cancer deaths were confirmed. In multivariable Cox regression models, hazard ratios (HRs) and 95% confidence intervals (CIs) for incident CRC across quartiles 1-4 of GlycA were: 1.00, 1.05 [0.74-1.51], 1.24 [0.89-1.77] , 1.55 [1.09-2.20], ptrend = 0.006; and for CRC mortality they were: 1.00, 0.92 [0.47-2.80] , 1.26 [0.67-2.37],and 1.46 [0.77-2.77] , ptrend = 0.14. Respective HRs and 95% CIs per 1-SD increment GlycA for colorectal cancer incidence and mortality were: 1.19 [1.06-1.35], p=0.004 and 1.24 [1.00-1.54] , p=0.05. HsCRP, fibrinogen, and sICAM were not significantly associated with incident CRC, and hsCRP and sICAM were not significantly associated with CRC mortality; respective ptrend & gt;0.05 across quartiles 1-4 of GlycA for incident CRC and CRC mortality. Conclusions: In this prospective study of initially healthy women, baseline GlycA levels were associated with incident colorectal cancer and mortality, consistent with a possible role for protein glycans in the pathogenesis of colorectal cancer. Citation Format: Paulette D. Chandler, Akintunde Akinkuolie, Deirdre Tobias, Lu Wang, M.V. Moorthy, Paul M. Ridker, I-Min Lee, JoAnn E. Manson, Julie E. Buring, James Otvos, Samia Mora. Novel protein glycan biomarker and future colorectal cancer. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B79.
    Type of Medium: Online Resource
    ISSN: 1541-7786 , 1557-3125
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2097884-4
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 24 ( 2020-12-15), p. 5597-5605
    Abstract: In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by canakinumab has been shown to significantly reduce lung cancer incidence and mortality. Here we performed molecular characterization of CANTOS patients who developed lung cancer during the study, including circulating tumor DNA (ctDNA) and soluble inflammatory biomarker analysis. Catalogue of Somatic Mutations in Cancer (COSMIC) database ctDNA mutations were detected in 65% (46/71) of the CANTOS patients with lung cancer, with 51% (36/71) having detectable ctDNA at the time point closest to lung cancer diagnosis and 43% (29/67) having detectable ctDNA at trial randomization. Mutations commonly found in lung cancer were observed with no evidence of enrichment in any mutation following canakinumab treatment. Median time to lung cancer diagnosis in patients with (n = 29) versus without (n = 38) detectable COSMIC ctDNA mutations at baseline was 407 days versus 837 days (P = 0.011). For serum inflammatory biomarker analysis, circulating levels of C-reactive protein (CRP), IL6, IL18, IL1 receptor antagonist, TNFα, leptin, adiponectin, fibrinogen, and plasminogen activator inhibitor-1 were determined. Patients with the highest level of baseline CRP or IL6, both downstream of IL1β signaling, trended toward a shorter time to lung cancer diagnosis. Other inflammation markers outside of the IL1β pathway at baseline did not trend with time to lung cancer diagnosis. These results provide further evidence for the importance of IL1β-mediated protumor inflammation in lung cancer and suggest canakinumab's effect may be mediated in part by delaying disease progression of diverse molecular subtypes of lung cancer. Significance: These findings suggest that targeting the IL1β inflammatory pathway might be critical in reducing tumor-promoting inflammation and lung cancer incidence.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Prevention Research, American Association for Cancer Research (AACR), Vol. 8, No. 10_Supplement ( 2015-10-01), p. A08-A08
    Abstract: Background: Lipids are involved in the inflammatory response and are the major cell membrane components essential for various biological functions including cell growth and division of normal and malignant tissues. Circulating lipoproteins and lipids have different associations with cancer risk. Objective: To determine whether baseline levels of blood lipid markers were associated with subsequent cancer risk in initially healthy women free of cancer and cardiovascular disease. Design: Observational follow-up of a randomized trial. The primary cancer end points included total (excluding nonmelanoma skin), breast, colorectal, ovarian, and endometrial cancers, and cancer mortality. Setting: A total of 39,876 healthy female health professionals aged 45 years or older in the Women's Health Study (WHS, ClinicalTrials.gov: NCT00000479. Baseline blood was collected from 27,495 women with median follow-up of 19 years. Methods: We examined the prospective association between baseline total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C] , high-density lipoprotein cholesterol [HDL-C], triglycerides [TG] ), apolipoprotein A-I [Apo A-I] and B100 [Apo B100] and risk of total cancer, breast, ovarian, endometrial, and colorectal cancer among all women with no prior diagnosis of cancer in the WHS. Plasma lipid biomarkers were categorized into quartiles. All cancer endpoints were confirmed from medical records. We used Cox proportional Hazard Regression to estimate hazard ratios (HRs) representing comparison of quartile 4 (highest) to quartile 1 (lowest) adjusted for cancer risk factors. Results: A total of 4,001 incident cancer cases (1657 breast, 345 colorectal, 315 endometrial, and 165 ovarian) and 1175 cancer deaths were confirmed. Most of the lipid biomarkers were not significantly associated with total cancer risk, except a significant inverse association was observed between ApoA-I and total cancer incidence (adjusted HR: 0.83 [95% CI, 0.75 to 0.92]; ptrend & lt;0.0001). For individual cancer site, we observed significant associations for several lipids with colorectal cancer for TG (HR: 1.61 [1.15 to 2.24]; ptrend & lt;0.001), Apo B100 (HR: 1.41 [1.02 to1.94]; ptrend=0.01), TG/HDL-C (HR, 1.76 [1.25 to 2.48] ; ptrend=0.003) , and HDL-C (HR: 0.68 [0.49 to 0.95]; ptrend=0.01). Similarly, an increased ovarian cancer risk was seen with higher TC (HR, 1.52 [CI, 0.98 to 2.35] ; ptrend = 0.02). However, both TG and TG/HDL were found significantly inversely associated with breast cancer risk (TG:HR, 0.78 [CI, 0.67 to 0.91]; ptrend = 0.002; TG/HDL: HR, 0.77 [CI, 0.67 to 0.90] ; ptrend = 0.001). LDL-C was not significantly associated with risk of total cancer or any site-specific cancers. Conclusions: In this prospective cohort of middle-aged and older US women, we found significant associations between plasma lipid markers including TC, HDL-C, TG, Apo A1, and Apo B100 and total cancer and some site-specific cancers. Specifically, colorectal cancer is associated with various lipids. Future studies are needed to confirm or refute these findings and explore the mechanisms underlying these associations. Citation Format: Paulette D. Chandler, Shumin Zhang, Jennifer H. Lin, JoAnn E. Manson, Julie E. Buring, M V. Moorthy, Paul Ridker, Kevin P. McMahon, I-Min Lee, Yiqing Song, Lu Wang. Lipid biomarkers and cancer risk: Long-term observational follow-up of cancer in the Women's Health Study. [abstract]. In: Proceedings of the Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2014 Sep 27-Oct 1; New Orleans, LA. Philadelphia (PA): AACR; Can Prev Res 2015;8(10 Suppl): Abstract nr A08.
    Type of Medium: Online Resource
    ISSN: 1940-6207 , 1940-6215
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2422346-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...